Skip to main content
  • EFC18241

    This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab…

    Investigator
    Michael J Haller
    Ages
    1 Year - 25 Years
    Sexes
    All
  • GNTI-122-T1D-1001

    This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood…

    Investigator
    Brittany S Bruggeman
    Ages
    18 Years - 45 Years
    Sexes
    All
  • SAFEGUARD

    This is a Phase 2b, investigator* and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

    Investigator
    Laura Jacobsen
    Ages
    5 Years - 40 Years
    Sexes
    All